Molecular Partners AG
MOLN
Rank in Stocks
#18857
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Share Price
$3.09
Last synced: 2026-11-09
Market Cap
$120.65M
Change (1 day)
-1.59%
Change (1 year)
-23.33%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Molecular Partners AG (MOLN)
Category
Healthcare
EPS for Molecular Partners AG (MOLN)
EPS as of September 2026 TTM: $-1.62
According to Molecular Partners AG's latest financial reports, its current EPS (TTM) is $-1.62. At the end of 2025 the company had an EPS of $-2.08, a decrease compared to its 2024 EPS of $-1.76.
EPS history for Molecular Partners AG from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.62 | -22.23% |
| 2025 | $-2.08 | 18.12% |
| 2024 | $-1.76 | -21.67% |
| 2023 | $-2.25 | -157.24% |
| 2022 | $3.93 | -273.77% |
| 2021 | $-2.26 | -19.14% |
| 2020 | $-2.79 | 59.95% |
| 2019 | $-1.75 | -1.80% |
| 2018 | $-1.78 | 42.12% |
| 2017 | $-1.25 | 40.00% |
| 2016 | $-0.89 | 11,664.47% |
| 2015 | $-0.01 | -94.97% |
| 2014 | $-0.15 | -136.41% |
| 2013 | $0.41 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,068.10% |
US
|
|
| $-7.07 | 337.07% |
US
|
|
| $-5.29 | 227.03% |
AU
|
|
| $12.88 | -896.25% |
BE
|
|
| $21.56 | -1,432.84% |
NL
|
Questions about Molecular Partners AG's earnings per share (EPS)
What is Molecular Partners AG's earnings per share (EPS)?
Molecular Partners AG's earnings per share (EPS) over the last twelve months is $-1.62, as of Sep 2026.
What was Molecular Partners AG's earnings per share (EPS) in 2025?
In 2025, Molecular Partners AG's earnings per share (EPS) was $-2.08, compared with $-1.76 in 2024.
How has Molecular Partners AG's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Molecular Partners AG's earnings per share (EPS) was highest in 2022 ($3.93) and lowest in 2020 ($-2.79).
How does Molecular Partners AG's earnings per share (EPS) compare with similar companies?
Molecular Partners AG's earnings per share (EPS) ($-1.62) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.